Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05534750
Other study ID # APHP210084
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 20, 2023
Est. completion date May 2025

Study information

Verified date October 2023
Source Assistance Publique - Hôpitaux de Paris
Contact Nicolas VEZIRIS, PU-PH
Phone 01 49 28 30 41
Email nicolas.veziris@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this work is to measure the early bactericidal activity of tedizolid, to compare it with the bactericidal activity of linezolid (reference molecule for the treatment of multidrug-resistant tuberculosis) and with that of standard quadruple therapy (reference treatment of drug susceptible tuberculosis).


Description:

This is a Phase 2, prospective, randomized, open-label controlled trial in 3 parallel groups comparing tedizolid with 2 standard treatments: linezolid (oxazolidinone whose anti-tuberculosis activity has already been demonstrated) and standard treatment for tuberculosis (quadruple therapy: isoniazid, rifampicin, ethambutol, pyrazinamide ). The objective is to measure the early bactericidal activity of tedizolid, to compare it with the bactericidal activity of linezolid and with that of standard quadruple therapy. Design: A multicentric, open-label, randomized clinical trial Sample size : 60 patients, 20 in each group Treatments groups: - Tedizolid arm: - Tedizolid (SIVEXTRO®), - 200 mg film-coated tablet - Dosage of 1 tablet per day to be taken in the morning for 7 days (taken with or without meals). - Linezolid arm (ZYVOXID®): - Linezolid arm (ZYVOXID®) - 600 mg film-coated tablet - Dosage of 2 tablets per day to be taken in the morning for 7 days (taken with or without meals). - Standard quadruple therapy arm: - Isoniazid (RIMIFON®) Tablets 50 or 200 mg Dosage 3 to 5mg / kg / day for 7 days to be taken in the morning on an empty stomach. - Rifampicin, dosage 10mg / kg / day for 7 days to be taken in the morning on an empty stomach. - Ethambutol 15-20mg / kg / day for 7 days to be taken in the morning on an empty stomach. - Pyrazinamide 20-25mg / kg / day for 7 days to be taken in the morning on an empty stomach. Treatment duration : 7 days Assessement: After signing the consent, patients will be randomized, a sputum sample will be taken before the first drug intake. Then, patients will be treated for 7 days depending on the randomization group (tedizolid, linezolid or standard quadruple therapy). Daily, a sputum of at least 2 mL will be withdrawn from the patients for 7 days. A consultation with blood test will be carried out on D30, date of the patient's end of participation. No interim analysis is planned. Analysis will be performed at the end of the study after data review and freezing of database.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date May 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Age = 18 years old and <75 years old - Woman on childbearing age should be on effective contraception during the duration of the study and up to 6 months after treatment; a mechanical contraception (use of condom) will be strongly recommended - Male (effective contraception must be used during duration of the study and up to 3 months after treatment) - Patient with a first infection with Mycobacterium tuberculosis of pulmonary localization suspected by the presence of a clinical pulmonary symptomatology, a chest X-ray or an abnormal chest computed tomography, and the positive microscopic examination of a sputum (AFB +, presence of AFB) with confirmation of tuberculosis by a genotypic test demonstrating no resistance to rifampicin, without clinical signs of extra-thoracic involvement - State medical assistance application being processed ( If patient does not benefit from social security), - Signature of informed consent Exclusion Criteria: - Resistance to one of the anti-tuberculosis drugs used detected by a genotypic test in accordance with the recommendations of the High Council of Public Health of 2015; - History of anti-tuberculosis treatment; - History of treatment in the previous two years with one of the antibiotics evaluated in this trial lasting more than one month; - Absolute contraindication to the use of at least one of the test molecules (isoniazid, rifampicin, ethambutol, pyrazinamide, linezolid, tedizolid); - Tuberculosis having, in the opinion of the investigator, severity criteria not allowing to wait 7 days before starting standard treatment (oxygenorequirement, severe immunosuppression, extra-pulmonary involvement, any sign of severity requiring treatment in intensive care unit); - HIV-infected patient receiving protease inhibitors whose antiviral treatment cannot be changed and therefore cannot receive rifampicin; or any other drug contraindicated with one of the study treatments (the list of contraindicated drugs is detailed in the following non-inclusion criteria). - Neoplastic pathology during treatment with chemo and / or radiotherapy; - Decompensated cirrhosis; - Pregnancy, desire to become pregnant, breast-feeding (for women of childbearing potential, contraception should be used for the duration of the study and up to 6 months after treatment, mechanical contraception will be strongly recommended and up to 3 months after treatment); - Protected adults (under guardianship, curatorship) and under safeguard of justice - Significant laboratory abnormalities (hemoglobin <9g / dl, polynuclear neutrophils <500 / mm3, platelets <50,000 / mm3, creatinine clearance <30ml / min, ASAT or ALAT> 3N, and total bilirubin> 3N) - Hyperuricaemia - Porphyria - Optic neuritis or peripheral neuropathy - BMI= 16 kg/m2 - Participation in other interventional research - Current treatment with one or more medications contraindicated in combination with linezolid: Linezolid should not be used in patients treated with monoamine oxidase A or B inhibitors (for example: phenelzine, isocarboxacid, selegiline, moclobemide) or who received one of these products in the previous two weeks - Current treatment with one or more medications contraindicated in combination with quadritherapy: - Combination with bictegravir, cobicistat, daclatasvir, dasabuvir, delamanid, grazoprevir/elbasvir, protease inhibitors boosted by ritonavir, isavuconazole, ledipasvir, lurasidone, midostaurin, ombitasvir/paritaprevir, praziquantel, rilpivirine, sofosbuvir, velpatasvir, voriconazole, voxilaprevir - Gastrointestinal topicals, antacids and adsorbents and salts and aluminum hydroxides

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tedizolid arm (SIVEXTRO®)
Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
Linezolid arm (ZYVOXID®)
Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
Standard quadruple therapy arm
Patients will be taken : ISONIAZIDE : o A dosage of 5mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Isoniazid (RIMIFON®) RIFAMPICINE : o A dosage of 10mg / kg / day for 7 days (to be taken in the morning on an empty stomach) ETHAMBUTOL : o A dosage of 15-20mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Ethambutol PYRAZAMIDE : o A dosage of 20-25mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Pyrazinamide Then, the early bactericidal activity will be measured and compared to the other arms.

Locations

Country Name City State
France Bacteriology department- Hôpital Saint-Antoine Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of the early bactericidal activity (EBA) of tedizolid (200mg / day) at the end of the first 2 days of treatment (D3). The measurement will be done as follow: EABD1D3= (log10 number of CFU (CFU= colony forming unit) of M. tuberculosis on medium 7H11/mL of sputum on D1) - (log10number of CFU of M. tuberculosis on medium 7H11/mL of sputum on D3)/2. Day 3
Secondary Evaluation of the early bactericidal activity (EBA) of tedizolid between Day 3 and Day 8 The measurement will be done as follow: EBAD3D8= (log10 number of CFU (CFU=colony forming unit) of M. tuberculosis on medium 7H11/mL of sputum on D3) - ( log10 number of CFU of M. tuberculosis on medium 7H11/mL of sputum at D8)/5 Day 8
Secondary Comparison of the early bactericidal activity (EBA) of tedizolid between Day 1 and Day 3 Compare the early bactericidal activity of tedizolid 200 mg / day to that of linezolid 1200 mg / day between Day 1 and Day 3 Day 3
Secondary Comparison of the early bactericidal activity (EBA) of tedizolid between Day 3 and Day 8 Compare the early bactericidal activity of tedizolid 200 mg / day to that of linezolid 1200 mg / day between Day 1 and Day 3 and between Day 3 and Day 8 Day 8
Secondary Comparison of the early bactericidal activity of tedizolid 200 mg / day to that of standard quadruple therapy between Day 1 and Day 3 Compare the early bactericidal activity of tedizolid 200 mg / day to that of standard quadruple therapy between Day 1 and Day 3 Day 3
Secondary Comparison of the early bactericidal activity of tedizolid 200 mg / day to that of standard quadruple therapy between Day 3 and Day 8 Compare the early bactericidal activity of tedizolid 200 mg / day to that of standard quadruple therapy between Day 3 and Day 8 Day 8
Secondary Tedizolid pharmacokinetics'measurement To measure the total and free concentration of tedizolid measured at 0, 1, 3, 5 and 24hours 24hours
Secondary Evaluation of Tedizolid's tolerance on hemoglobin Rate of patients with hemoglobin <9, g / dl, which will lead to premature discontinuation of the administration of the treatment 30 days
Secondary Evaluation of Tedizolid's tolerance on polynuclear neutrophils Rate of patients with polynuclear neutrophils <500 / mm3, which will lead to premature discontinuation of the administration of the treatment 30 days
Secondary Evaluation of Tedizolid's tolerance on platelets Rate of patients with platelets <30,000 / mm3 which will lead to premature discontinuation of the administration of the treatment 30 days
Secondary Evaluation of Tedizolid's tolerance on creatinine clearance Rate of patients with creatinine clearance <30ml / min which will lead to premature discontinuation of the administration of the treatment 30 days
Secondary Evaluation of Tedizolid's tolerance on AST/ALT Rate of patients with AST or ALT> 5N which will lead to premature discontinuation of the administration of the treatment 30 days
Secondary Evaluation of Tedizolid's tolerance on bilirubin Rate of patients with total bilirubin> 5N which will lead to premature discontinuation of the administration of the treatment 30 days
Secondary Evaluation of Tedizolid's tolerance on dress syndrome Rate of patients with dress syndrome which will lead to premature discontinuation of the administration of the treatment. 30 days
Secondary Evaluation of Tedizolid's tolerance on optic neuropathy Rate of patients with optic neuropathy which will lead to premature discontinuation of the administration of the treatment 30 days
Secondary Evaluation of Tedizolid's tolerance on peripheral neuropathy Rate of patients with rapidly progressive peripheral neuropathy, which will lead to premature discontinuation of the administration of the treatment 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2